Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Rating of “Hold” by Brokerages

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) have earned an average recommendation of “Hold” from the five research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $11.9750.

A number of equities analysts recently weighed in on VALN shares. Guggenheim set a $11.00 price objective on shares of Valneva in a research report on Thursday, April 16th. The Goldman Sachs Group lowered shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective on the stock. in a research report on Wednesday, April 22nd. Finally, Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st.

Valneva Stock Performance

Shares of VALN opened at $5.26 on Thursday. The company has a current ratio of 2.14, a quick ratio of 1.60 and a debt-to-equity ratio of 2.14. The firm has a market cap of $499.12 million, a PE ratio of -2.81 and a beta of 1.75. The company’s 50 day simple moving average is $5.82 and its 200-day simple moving average is $8.18. Valneva has a 12-month low of $5.06 and a 12-month high of $12.25.

Valneva (NASDAQ:VALN) last announced its earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%.The business had revenue of $35.77 million for the quarter. As a group, equities analysts predict that Valneva will post -1 EPS for the current year.

Hedge Funds Weigh In On Valneva

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in Valneva in the 4th quarter valued at $94,000. China Universal Asset Management Co. Ltd. purchased a new position in Valneva in the 4th quarter valued at $44,000. JPMorgan Chase & Co. purchased a new position in Valneva in the 3rd quarter valued at $124,000. VSM Wealth Advisory LLC grew its position in Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the last quarter. Finally, Marex Group plc purchased a new position in Valneva in the 2nd quarter valued at $64,000. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.